NFκB inhibition secondary to melatonin treatment in LNCaP and 22Rv1 prostate cancer cells was repeated by Sun Liu et al., further verifying NFκB as a likely downstream target of melatonin [60]. This evidence concerns the gene NFKB1 and prostate cancer.